Ready for take­off: J&J's con­sumer health unit Ken­vue files for of­fi­cial sep­a­ra­tion

J&J’s con­sumer health unit Ken­vue filed for an IPO on Wednes­day, set­ting in mo­tion the long-an­tic­i­pat­ed plans for its of­fi­cial spin­off.

Ken­vue is tout­ing it­self as the “world’s largest pure-play con­sumer health com­pa­ny,” with pop­u­lar brands such as Neu­tro­ge­na, Tylenol, Band-Aid and Lis­ter­ine in tow. The unit raked in just over $15.1 bil­lion in 2021. Up­on un­veil­ing its new name and look back in Sep­tem­ber, J&J said Ken­vue would be­come an in­de­pen­dent com­pa­ny by No­vem­ber 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER